The human apolipoprotein (apo) E gene is polymorphic, with three common alleles (#{128}2, #{128}3, #{128}4) coding for three isoforms (E2, E3, E4). The isoforms differ from each other by a single amino acid substitution, and also differ in their binding affinity for the four apo E receptors. Apo E polymorphism is an important determinant of risk for the development of cardiovascular and Alzheimer diseases, the prevalence of the #{128}4 allele being increased in both kinds of patients compared with control subjects. Furthermore, the prevalence of the #{128}4 allele differs among populations (range 5-40%, respectively, for Taiwanese and Papua New Guineans). Genotyping or phenotyping needs to be introduced in clinical laboratories. The choice of the method should be based on the types of patients who are examined. The apo E genotype is also a determinant of apo E plasma concentration. Standardization of apo E measurement is an important prerequisite before investigating the clinical interest of plasma apo E concentration. Determination of apo E genotype/ phenotype and later the plasma concentration are expected to yield useful clinical laboratory information.
The human apolipoprotein (apo) E gene is polymorphic, with three common alleles (#{128}2, #{128}3, #{128}4) coding for three isoforms (E2, E3, E4). The isoforms differ from each other by a single amino acid substitution, and also differ in their binding affinity for the four apo E receptors. Apo E polymorphism is an important determinant of risk for the development of cardiovascular and Alzheimer diseases, the prevalence of the #{128}4 allele being increased in both kinds of patients compared with control subjects. Furthermore, the prevalence of the #{128}4 allele differs among populations (range 5-40%, respectively, for Taiwanese and Papua New Guineans). Genotyping or phenotyping needs to be introduced in clinical laboratories. The choice of the method should be based on the types of patients who are examined. The apo E genotype is also a determinant of apo E plasma concentration. Standardization of apo E measurement is an important prerequisite before investigating the clinical interest of plasma apo E concentration. Determination of apo E genotype/ phenotype and later the plasma concentration are expected to yield useful clinical laboratory information. Apo E, known for more than 20 years, has been associated with the risk of developing cardiovascular diseases. Moreover, since 1993, this apolipoprotein has come to the fore because of its implication in Alzheimer disease (AD) and aging. Is apo E3 a protector; is apo E4 implicated in the formation of senile plaques by aggregation with other proteins; is apo E2 really a longevity gene?
This review, after a look at the structure of apo E, its variants, and their biogenesis, will reappraise the role of apo E in cardiovascular disease and will focus on its more recently discovered links with other pathologies, particularly neurodegenerative diseases.
The interested reader is directed to more specialized reviews on apo E and cardiovascular disease (1, 3), apo E and AD (4) , and structural/functional considerations (5). 194 (9) . In plasma, 90% of the protein is desialylated. The functional relevance of this phenomenon is at present not understood in terms of function and physiological properties of apo E (10), given that glycosylation of apo E has no effect on the production and the secretion of the protein into the circulation (8). Interestingly, the first hypothesis of apo E heterogeneity arose from results showing differing degrees of sialylation of the mature protein present in the different lipoparticles, or in tissues (10). In humans, apo E presents a genetic polymorphism (11, 12) . This was first suggested by isoelectric focusing (IEF) of apo E and subsequently confirmed by direct sequencing of the cDNA. Apo E is present as three major isoforms, named apo E2, E3, and E4 (6, 13). Apo E3 is the most frequent isoform in the general popula-U Phospholipid-bindlng sIte tion. The molecular basis of apo E polymorphism is cysteine-arginine interchanges. Apo E3 contains a single cysteine at residue 112 and an arginine at position 158; apo E2 contains cysteine residues at both positions 112 and 158; and apo E4 contains arginine residues at both positions. This polymorphism leads to the presence of six different phenotypes in the human population:
Structure
three homozygous (E3/3, E2/2, and E414) and three heterozygous (E2/3, E2/4, and E3/4). Although apo E is one of the best-characterized apolipoproteins in terms of structure-function relationships, the particular structural properties of each isoform that explain the differences in reactivity remain poorly understood.
Apo E is well known to differ from other apolipoproteins in its tertiary structure.
From the ChouFasman algorithm, apo E is predicted to be highly helical and segregated into two fragments separated by a large segment whose structure is predicted to be random (14) . Several lines of evidence suggest that apo E is refolded into two independent structural domains ( Fig. 1 
Genotyping techniques.
To avoid these problems of phenotyping, apo E genotyping has been developed. Fig. 2 
Apo E Polymorphism in Cardiovascular Diseases
Historically, a link between apo E polymorphism and atherosclerosis was first established with the observation that patients with type III hyperlipoproteinemia and with the ape E 2/2 phenotype had premature coronary heart disease (11). Therefore, the polymorphism of apo E has been extensively studied, and evidence has accumulated that it is a major determinant of the interindividual variation in the initiation and progression of atherosclerosis
(87).
Numerous population studies (Table  1) The average effect of the #{128}4 allele is to increase significantly the concentration of total cholesterol in a healthy population, thus conferring a relative predisposition to atherosclerosis. In contrast, the average effect of the #{128}2 allele is to decrease the cholesterol concentration, this cholesterollowering effect being two to three times the cholesterolraising effect of the #{128}4 allele, depending on the population studied.
Boerwinkle, in collaboration with our group (32), has estimated for our Lorraine (France) population that the average effect of the #{128}2 allele was to reduce total plasma cholesterol by 0.52 mmol/L, whereas the #{128}4 allele increased this by 0.26 mmoIfL. In all, 8% of total cholesterol variability was attributable to apo E polymorphism.
Very (182, 183) . However, Aj3 deposits also exist in patients without AD (184) . Apo E is colocalized with A in amyloid plaques in old rhesus monkeys (185) .
The neurotoxicity of A13 is not totally resolved (186). Some arguments are in favor of a specific effect of A3 (195, 196) . Ape E4 might also compete for heparan sulfate proteeglycans with several growth or regulating factors. Clearly, therefore, apo E, especially apo E4, appears to play a central role in the development of several neurodegenerative processes (197, 198) . This has important implications for the design of preventive therapeutic strategies, mimicking the metabolic functions of ape E3 or ape E2 that do not seem to be implicated in pathology.
However, one must exercise caution in this because ape E4 has not been demonstrated to have a direct role in the pathogenesis of AD.
Apo E Polymorphism in Other Neurological Diseases
One of the main difficulties in the study of dementia is the clinical classification of patients into distinct pathological groups. To investigate the specific role of In summary, the determination of ape E polymorphism is of great clinical interest.
Apo E Concentrations in Plasma and Other Biological Fluids
We know now the relative effect of ape E polymorphism on ape E concentrations in plasma but this apolipoprotein is difficult to measure accurately.
Methods and Standardization
The There being no standardization in methodology and the reagents having been produced "inhouse" with protocols established by each research group, it is perhaps unsurprising that the mean reported values in healthy subjects vary widely (between 30 and 120 mg/L). Moreover, some of the studies have been performed with very few subjects (four or six). The effect of the different phenotypes on apo E concentration could also be partly responsible for the high degree of scatter. In addition, results are expressed as means ± SD, even though the distribution of ape E concentration is probably not gaussian. That said, variation in the type of specimen used may also affect the results:
Biological Variations of Plasma Ape E Concentration
Apart from the analytical problems described above, the results obtained for ape E plasma concentration in healthy people might also vary as a function of different biological factors. A few factors that might affect the biological variations of ape E concentration have been considered.
We present in Table 4 275, 276) and it evidently cannot be performed at the patient's request.
But given the possible linkage of #{128}2 with longevity, the balance between the "bad" (#{128}4) and "good" (#{128}2) alleles might hasten the general introduction of apo E genotyping into clinical chemistry. 
